OncoMatch/Clinical Trials/NCT06717711
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
Is NCT06717711 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Low-intensity Extracorporeal Shock Wave Therapy (LiESWT) and PDE5 inhibitor (tadalafil) for prostate carcinoma.
Treatment: Low-intensity Extracorporeal Shock Wave Therapy (LiESWT) · PDE5 inhibitor (tadalafil) — This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical Prostatectomy (RP) erectile dysfunction (ED) in addition to PDE5 inhibitors (PDE5i) versus PDE5i alone. Our hypothesis is that early andrological rehabilitation that combines Li-ESWT and PDE5i could lead to faster and better recovery of valid erections for intercourse, with a greater rate of postoperative International Index of Erectile Function-5 (IIEF-5) compared to patients receiving PDE5i alone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Grade: ISUP grade ≤2 (ISUP)
Prostate Cancer ISUP grade ≤2 and cT≤2 at prostate biopsy; Prostate Cancer ISUP grade ≤2 pT<3b and at final pathology
Demographics
Prior therapy
Must have received: robot-assisted radical prostatectomy (nerve sparing RARP)
undergoing nerve sparing RARP
Cannot have received: pelvic radiotherapy
patients submitted to pelvic radiotherapy
Cannot have received: androgen deprivation
patients submitted to...androgen deprivation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06717711 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy, androgen deprivation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages